CD274 and neoplasm: In addition, expression analyses of immune checkpoints, e.g. PD-L1, may help identifying subgroups of patients with mismatch repair-proficient tumours who may benefit from additional adjuvant immune checkpoint inhibition to reduce the recurrence rate and improve survival.